...
首页> 外文期刊>Mechanisms of Ageing and Development >Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice
【24h】

Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice

机译:多靶铁螯合剂M30对小鼠年龄相关性改变的神经保护

获取原文
获取原文并翻译 | 示例
           

摘要

Based on a multimodal drug design paradigm, we have synthesized a multifunctional non-toxic, brain permeable iron chelating compound, M30, possessing the neuroprotective N-propargyl moiety of the anti-Parkinsonian drug, monoamine oxidase (MAO)-B inhibitor, rasagiline and the antioxidant-iron chelator moiety of an 8-hydroxyquinoline derivative of the iron chelator, VK28. Here, we report that a chronic systemic treatment of aged mice with M30 (1 and 5. mg/kg; 4 times weekly for 6 months), had a significant positive impact on neuropsychiatry functions and cognitive age-related impairment. M30 significantly reduced cerebral iron accumulation as demonstrated by Perl's staining, accompanied by a marked decrease in cerebral β-amyloid plaques. In addition, our results demonstrate that M30 caused a significant inhibition of both MAO-A and -B activities in the cerebellum of aged mice, compared with vehicle-treated aged control mice. In summary, the present study indicates that the novel MAO inhibitor/iron chelating drug, M30, acting against multiple brain targets could reverse age-associated memory impairment and provide a potential treatment against the progression of neurodegeneration in ageing.
机译:基于多模式药物设计范例,我们合成了多功能,无毒,可透脑的铁螯合化合物M30,具有抗帕金森病药物的神经保护性N-炔丙基部分,单胺氧化酶(MAO)-B抑制剂,雷沙吉兰和铁螯合剂VK28的8-羟基喹啉衍生物的抗氧化剂-铁螯合剂部分。在这里,我们报道了M30(1和5. mg / kg;每周4次,共6个月)对老年小鼠的慢性全身治疗,对神经精神病学功能和与认知年龄相关的损伤具有明显的积极影响。如Perl染色所示,M30显着降低了脑铁的蓄积,并伴有脑β-淀粉样斑块的明显减少。此外,我们的研究结果表明,与媒介物治疗的老年对照小鼠相比,M30对老年小鼠小脑的MAO-A和-B活性均具有显着抑制作用。总而言之,本研究表明,针对多个脑靶的新型MAO抑制剂/铁螯合药物M30可以逆转与年龄相关的记忆障碍,并为对抗衰老中神经退行性疾病的发展提供潜在的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号